Daphne Ruth Friedman
Associate Professor of Medicine
My area of expertise is in leukemias and lymphomas, including Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. My research interests are focused on improving treatment options for patients with hematologic malignancies, through laboratory and clinical research. I am also a staff physician at the Durham VA Medical Center, and am deeply committed to expanding treatment options for veterans, including working on clinical trials for multiple myeloma, prostate cancer, and lung cancer at the Durham VA.
Current Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2013
Contact Information
- 508 Fulton Street (111g), Durham, NC 27705
- 508 Fulton Street (111g), Durham VA Medical Center, Durham, NC 27705
-
daphne.friedman@duke.edu
(919) 286-6944
- Background
-
Education, Training, & Certifications
- Fellow in Hematology-Oncology, Medicine, Duke University 2005 - 2008
- Medical Resident, Medicine, University of Maryland, College Park 2002 - 2005
- M.D., University of Maryland, College Park 2002
-
Previous Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2017 - 2020
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2017
- Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2008 - 2013
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2008
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Friedman, Daphne R., Ahmad S. Halwani, and Michael J. Kelley. “Reply to B.L. King-Kallimanis et al.” Jco Clin Cancer Inform 6 (July 2022): e2200075. https://doi.org/10.1200/CCI.22.00075.Full Text Link to Item
-
Friedman, Daphne R., Vikas Patil, Chunyang Li, Kelli M. Rassmussen, Zachary Burningham, Susan Hamilton-Hill, Michael J. Kelley, and Ahmad S. Halwani. “Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience.” Jco Clin Cancer Inform 6 (February 2022): e2100086. https://doi.org/10.1200/CCI.21.00086.Full Text Link to Item
-
Chiang, Ryan S., Daphne R. Friedman, Kelsey McHugh, Sendhilnathan Ramalingam, and Vishal Vashistha. “Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 Mutations.” Fed Pract 38, no. 1 (January 2021): 40–43. https://doi.org/10.12788/fp.0073.Full Text Link to Item
-
Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.” Br J Haematol 186, no. 4 (August 2019): 637. https://doi.org/10.1111/bjh.15934.Full Text Link to Item
-
Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.” Br J Haematol 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.Full Text Link to Item
-
Friedman, Daphne R., Kenneth R. Carson, and J Brice Weinberg. “Reflections on and future of hematologic malignancies research in the Veterans Health Administration.” Semin Oncol 46, no. 4–5 (2019): 346–50. https://doi.org/10.1053/j.seminoncol.2019.09.004.Full Text Link to Item
-
Friedman, Daphne R., Eross Guadalupe, Alicia Volkheimer, Joseph O. Moore, and J Brice Weinberg. “Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.” Br J Haematol 183, no. 5 (December 2018): 747–54. https://doi.org/10.1111/bjh.15632.Full Text Link to Item
-
Friedman, Daphne R. “Lipids and Their Effects in Chronic Lymphocytic Leukemia.” Ebiomedicine 15 (February 2017): 2–3. https://doi.org/10.1016/j.ebiom.2016.12.001.Full Text Link to Item
-
Friedman, Daphne R., Alexander B. Sibley, Kouros Owzar, Kari G. Chaffee, Susan Slager, Neil E. Kay, Curtis A. Hanson, et al. “Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study.” Am J Hematol 91, no. 7 (July 2016): 687–91. https://doi.org/10.1002/ajh.24376.Full Text Link to Item
-
Holohan, Brody, Moriah M. Hagiopian, Tsung-Po Lai, Ejun Huang, Daphne R. Friedman, Woodring E. Wright, and Jerry W. Shay. “Perifosine as a potential novel anti-telomerase therapy.” Oncotarget 6, no. 26 (September 8, 2015): 21816–26. https://doi.org/10.18632/oncotarget.5200.Full Text Link to Item
-
Rempel, Rachel E., Xiaolei Jiang, Paul Fullerton, Tuan Zea Tan, Jieru Ye, Jieying Amelia Lau, Seiichi Mori, Jen-Tsan Chi, Joseph R. Nevins, and Daphne R. Friedman. “Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.” Mol Cancer Ther 13, no. 12 (December 2014): 3219–29. https://doi.org/10.1158/1535-7163.MCT-13-0044.Full Text Link to Item
-
Friedman, Daphne R., Mark C. Lanasa, Patricia H. Davis, Sallie D. Allgood, Karen M. Matta, Danielle M. Brander, Youwei Chen, et al. “Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.” Leuk Lymphoma 55, no. 5 (May 2014): 1067–75. https://doi.org/10.3109/10428194.2013.824080.Full Text Link to Item
-
Nipp, Ryan D., Alicia D. Volkheimer, Evan D. Davis, Youwei Chen, J Brice Weinberg, and Daphne R. Friedman. “CD38 variation as a prognostic factor in chronic lymphocytic leukemia.” Leuk Lymphoma 55, no. 1 (January 2014): 191–94. https://doi.org/10.3109/10428194.2013.786070.Full Text Link to Item
-
Friedman, Daphne R. “"Primum non nocere": the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia.” Leuk Lymphoma 54, no. 3 (March 2013): 441–42. https://doi.org/10.3109/10428194.2012.727420.Full Text Link to Item
-
DiLillo, D. J., J. B. Weinberg, A. Yoshizaki, M. Horikawa, J. M. Bryant, Y. Iwata, T. Matsushita, et al. “Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.” Leukemia 27, no. 1 (January 2013): 170–82. https://doi.org/10.1038/leu.2012.165.Full Text Link to Item
-
Friedman, Daphne R., Joseph E. Lucas, and J Brice Weinberg. “Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia.” Plos One 8, no. 2 (2013): e57356. https://doi.org/10.1371/journal.pone.0057356.Full Text Link to Item
-
Lanasa, Mark C., Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, et al. “Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.” Leuk Lymphoma 53, no. 2 (February 2012): 218–24. https://doi.org/10.3109/10428194.2011.610012.Full Text Link to Item
-
Christensen, Dale J., Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, et al. “SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.” Blood 118, no. 15 (October 13, 2011): 4150–58. https://doi.org/10.1182/blood-2011-04-351072.Full Text Link to Item
-
Jima, Dereje D., Jenny Zhang, Cassandra Jacobs, Kristy L. Richards, Cherie H. Dunphy, William W. L. Choi, Wing Yan Au, et al. “Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.” Blood 116, no. 23 (December 2, 2010): e118–27. https://doi.org/10.1182/blood-2010-05-285403.Full Text Link to Item
-
Friedman, Daphne R., Lindsay A. Magura, Holly A. C. Warren, Jeremy D. Harrison, Louis F. Diehl, and J Brice Weinberg. “Statin use and need for therapy in chronic lymphocytic leukemia.” Leuk Lymphoma 51, no. 12 (December 2010): 2295–98. https://doi.org/10.3109/10428194.2010.520050.Full Text Link to Item
-
Mowery, Y. M., J. B. Weinberg, M. N. Kennedy, K. M. Bond, J. O. Moore, M. C. Lanasa, J. P. Gockerman, et al. “LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.” Leukemia 24, no. 9 (September 2010): 1580–87. https://doi.org/10.1038/leu.2010.150.Full Text Link to Item
-
Friedman, Daphne R., April D. Coan, Sophia K. Smith, James E. Herndon, and Amy P. Abernethy. “Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians.” Am J Hematol 85, no. 7 (July 2010): 528–32. https://doi.org/10.1002/ajh.21725.Full Text Link to Item
-
Friedman, Daphne R., J Brice Weinberg, William T. Barry, Barbara K. Goodman, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, et al. “A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.” Clin Cancer Res 15, no. 22 (November 15, 2009): 6947–55. https://doi.org/10.1158/1078-0432.CCR-09-1132.Full Text Link to Item
-
Friedman, D. R., A. H. Dupont, A. D. Coan, J. E. Herndon, K. L. Rowe, and A. P. Abernethy. “Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e20703.Link to Item
-
Zhang, Jenny, Dereje D. Jima, Cassandra Jacobs, Randy Fischer, Eva Gottwein, Grace Huang, Patricia L. Lugar, et al. “Patterns of microRNA expression characterize stages of human B-cell differentiation.” Blood 113, no. 19 (May 7, 2009): 4586–94. https://doi.org/10.1182/blood-2008-09-178186.Full Text Link to Item
-
Weinberg, J Brice, Alicia D. Volkheimer, Youwei Chen, Bethany E. Beasley, Ning Jiang, Mark C. Lanasa, Daphne Friedman, et al. “Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.” Am J Hematol 82, no. 12 (December 2007): 1063–70. https://doi.org/10.1002/ajh.20987.Full Text Link to Item
-
Friedman, D. R., and A. P. Abernethy. “Review of targeted cancer therapies for the palliative care provider Part 1: Small molecules.” Progress in Palliative Care 15, no. 4 (October 29, 2007): 171–76. https://doi.org/10.1179/096992607X177863.Full Text
-
Friedman, D. R., and A. P. Abernethy. “Review of targeted cancer therapies for the palliative care provider PART 2: Antibodies and conjugated agents.” Progress in Palliative Care 15, no. 5 (October 29, 2007): 225–32. https://doi.org/10.1179/096992607X217958.Full Text
-
Friedman, Daphne R., and Susan D. Wolfsthal. “Cocaine-induced pseudovasculitis.” Mayo Clin Proc 80, no. 5 (May 2005): 671–73. https://doi.org/10.4065/80.5.671.Full Text Link to Item
-
Vázquez, N., T. J. Walsh, D. Friedman, S. J. Chanock, and C. A. Lyman. “Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans.” Infect Immun 66, no. 1 (January 1998): 145–50. https://doi.org/10.1128/IAI.66.1.145-150.1998.Full Text Link to Item
-
-
Conference Papers
-
Basher, Fahmin, Micaela R. Scobie, Michael J. Kelley, Deepak Voora, and Daphne R. Friedman. “Utilization of Pharmacogenomics in Assessment of Tolerability and Efficacy of BTK Inhibitors.” In Blood, 140:11573–74. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-170301.Full Text
-
Lin, Chenyu, Micaela Scobie, Daphne Friedman, Michael Kelley, and Thomas Rodgers. “Prolymphocytic Progression of Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: A Nationwide Veterans Affairs Retrospective Review.” In Blood, 140:4176–77. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-157414.Full Text Link to Item
-
Friedman, Daphne R., Thomas D. Rodgers, Leah Szumita, and Elisa S. Weiss. “Identifying and Overcoming Barriers in Clinical Trial Enrollment for Veterans with Blood Cancers.” In Blood, 138:1920–1920. American Society of Hematology, 2021. https://doi.org/10.1182/blood-2021-146736.Full Text
-
Premji, Sarah, Cenk Yildirim, Nathanael Fillmore, Sarvari Yellapragada, Mary T. Brophy, Nhan Do, Quillan Huang, Daphne Ruth Friedman, and Nikhil C. Munshi. “Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system.” In Journal of Clinical Oncology, Vol. 39, 2021.Link to Item
-
Friedman, Daphne Ruth, Vikas Patil, Kelli Marie Rasmussen, Brian C. Sauer, Michael J. Kelley, and Ahmad Sami Halwani. “Implementation of the VA Symptom Assessment Scale (VSAS): Five-year experience.” In Journal of Clinical Oncology, 37:e23120–e23120. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e23120.Full Text
-
Chanfreau, Catherine, Kristine E. Lynch, Ji Won Chang, Daniel J. Becker, Daphne R. Friedman, Donna R. Rivera, Scott L. DuVall, and Julie A. Lynch. “Chronic myeloid leukemia among veterans from 2006 to 2015: Trends in utilization of tyrosine kinase inhibitors.” In Pharmacoepidemiology and Drug Safety, 27:102–3. WILEY, 2018.Link to Item
-
Chanfreau, Catherine, Kristine E. Lynch, Jiwon Chang, Daniel Jacob Becker, Daphne Ruth Friedman, Donna Rivera, Scott DuVall, and Julie Ann Lynch. “Chronic myeloid leukemia among veterans from 2006-2015: Trends in utilization of tyrosine kinase inhibitors.” In Journal of Clinical Oncology, 36:e18832–e18832. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e18832.Full Text
-
Friedman, Daphne R., Eross Guadeloupe, Alicia Volkheimer, and J Brice Weinberg. “Surface CD5 Protein Risk Stratifies Chronic Lymphocytic Leukemia.” In Blood, 128:3212–3212. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.3212.3212.Full Text
-
Vakkalanka, Swaroop, Kumar V. Penmetsa, Dawn Chasse, Youwei Chen, Srikant Viswanadha, Daphne R. Friedman, and J Brice Weinberg. “Abstract A24: The dual PI3K δ/γ inhibitor, RP6530, in combination with ibrutinib or fludarabine, synergistically enhances cytotoxicity in primary CLL cells in vitro.” In Clinical Cancer Research, 21:A24–A24. American Association for Cancer Research (AACR), 2015. https://doi.org/10.1158/1557-3265.hemmal14-a24.Full Text
-
Friedman, Daphne Ruth, Tiffany Stewart, Eross Guadalupe, Danielle M. Brander, David S. Pisetsky, and J Brice Weinberg. “Pan-caspase peptide inhibitor to induce primary chronic lymphocytic leukemia (CLL) cell death through a non-apoptotic and non-necroptotic mechanism.” In Journal of Clinical Oncology, 33:e13536–e13536. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13536.Full Text
-
Friedman, Daphne R., Tiffany Simms, Sallie D. Allgood, Danielle M. Brander, Peter Sportelli, Hari P. Miskin, Swaroop Vakkalanka, Srikant Viswanadha, J Brice Weinberg, and Mark C. Lanasa. “Abstract 4518: The PI3K-δ inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro.” In Cancer Research, 74:4518–4518. American Association for Cancer Research (AACR), 2014. https://doi.org/10.1158/1538-7445.am2014-4518.Full Text
-
Beri, Nina, Daphne R. Friedman, Tiffany M. Simms, Maragatha Kuchibhatla, J Brice Weinberg, and Mark C. Lanasa. “Molecular and Clinical Associations Between Vitamin D and Chronic Lymphocytic Leukemia.” In Blood, 122:5282–5282. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.5282.5282.Full Text
-
Friedman, Daphne R., Rachel E. Rempel, Xiaolei Jiang, and Joseph R. Nevins. “Modeling Variation in the Human Lymphoma Microenvironment with the E mu-Myc Mouse Model.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.Link to Item
-
Nipp, Ryan D., J Brice Weinberg, Alicia D. Volkheimer, Evan D. Davis, Youwei Chen, and Daphne R. Friedman. “CD38 Variation in Chronic Lymphocytic Leukemia.” In Blood, 120:4576–4576. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.4576.4576.Full Text
-
Friedman, Daphne R., and Joseph R. Nevins. “Genomic Heterogeneity in B-Cell Malignancies.” In Blood, 118:1480–1480. AMER SOC HEMATOLOGY, 2011.Link to Item
-
Weinberg, J Brice, David J. DiLillo, Yohei Iwata, Takashi Matushita, Karen M. Matta, Guglielmo M. Venturi, Giandomenico Russo, et al. “Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells.” In Blood, 118:132–33. AMER SOC HEMATOLOGY, 2011.Link to Item
-
Friedman, Daphne R., Patricia H. Davis, Mark C. Lanasa, Joseph O. Moore, Jon P. Gockerman, Taylor Nelson, Karen M. Bond, et al. “Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).” In Blood, 116:768–69. AMER SOC HEMATOLOGY, 2010.Link to Item
-
Friedman, Daphne R., Jeremy D. Harrison, Lindsay A. Magura, Holly A. Warren, Louis F. Diehl, and J Brice Weinberg. “Influence of Statin Therapy On the Clinical Course of Chronic Lymphocytic Leukemia.” In Blood, 114:926–926. AMER SOC HEMATOLOGY, 2009.Link to Item
-
Friedman, Daphne R., Yvonne Mowery, Margaret Kennedy, Karen M. Bond, J Brice Weinberg, and George J. Cianciolo. “The Anti-Inflammatory Investigational Agent LMP-420 Demonstrates in Vitro Cytotoxic Activity against Chronic Lymphocytic Leukemia Cells.” In Blood, 114:931–931. AMER SOC HEMATOLOGY, 2009.Link to Item
-
Jacobs, Cassandra L., Dereje D. Jima, Jenny Zhang, Cherie Dunphy, Kristy L. Richards, William W. L. Choi, Gopesh Srivastava, et al. “A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies.” In Blood, 114:948–49. AMER SOC HEMATOLOGY, 2009.Link to Item
-
Friedman, D. R., A. H. Dupont, A. D. Coan, J. E. Herndon, K. L. Rowe, and A. P. Abernethy. “Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Friedman, Daphne R., J Brice Weinberg, Anil Potti, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, Ning Jiang, et al. “A Genomic Strategy To Refine Prognosis and Predict Response to Therapy in Chronic Lymphocytic Leukemia.” In Blood, 110:3096–3096. American Society of Hematology, 2007. https://doi.org/10.1182/blood.v110.11.3096.3096.Full Text
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.